Transactions by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 28 March 2011, the following individuals, who are all persons discharging managerial responsibilities, were each granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's ordinary shares, or, in the case of David Smith, Lynn Tetrault and Tony Zook, over the Company's American Depositary Shares (ADSs). One ADS equals one ordinary share.
Name |
Shares awarded under AZIP |
Shares awarded under AZPSP |
Award price per share |
Anders Ekblom |
5,134 |
30,806 |
2853p |
Martin Mackay |
16,482 |
98,895 |
2853p |
Mene Pangalos |
6,554 |
39,327 |
2853p |
Jeff Pott |
8,824 |
52,944 |
2853p |
David Smith |
4,381 |
26,289 |
$46.18 |
Lynn Tetrault |
6,714 |
40,285 |
$46.18 |
Tony Zook |
16,178 |
97,069 |
$46.18 |
The AZIP was approved by shareholders at the Company's AGM in 2010. These AZIP awards are subject to a four-year performance period and a subsequent four-year holding period.
The performance hurdle that applies to these AZIP awards relates to dividends and dividend cover. A summary of the AZIP can be found in the AstraZeneca Annual Report and Form 20-F Information 2010 which is available on the Company's website www.astrazeneca.com.
The AZPSP was approved by shareholders at the Company's AGM in 2005. Awards made under the AZPSP may not generally vest before the third anniversary of the relevant date of grant, nor unless the specified performance target(s) have been met at the end of the three-year performance period which, for these awards, is 1 January 2011 to 31 December 2013.
The performance target that applies to these AZPSP awards relates to relative total shareholder return and cash flow. A summary of the AZPSP can be found in the AstraZeneca Annual Report and Form 20-F Information 2010 which is available on the Company's website www.astrazeneca.com.
A C N Kemp
Company Secretary
29 March 2011